National Biologics Facility


The National Biologics Facility offers custom manufacturing solutions for the development and production of the next generation of biological therapeutics. Combining extensive expertise and from state-of-the-art laboratories, the NBF provides the necessary infrastructure to bridge the gap between laboratory experiments and production of material for translation through pre-clinical and clinical trials. The facility staff of scientists and bioprocess engineers offer world-class expertise in molecular biology, antibody engineering (including phage display), mammalian cell culture and biopharmaceutical development.

Founded in 2007, the NBF was established to facilitate biotechnology companies and academic researchers in developing and validating biologics as an exciting and rapidly expanding class of human therapeutics.

Today, the NBF operates two nodes; one at the Australian Institute for Bioengineering and Nanotechnology (AIBN) at The University of Queensland, and a second, at the CSIRO Molecular Health Technologies in Melbourne. Each node offers unique infrastructure and services and together, work to enhance capabilities in early stage biologics technology in Australia.

Year of Establishment



cGMP, ISO9001

Access and Pricing

For more information on accessing the facility, or on its capabilities, equipment or pricing, please contact the Operations Manager.

Previous Clients

Since inception, the NBF has been instrumental in supporting a range of academic and industry partners. In collaboration with Queensland Health, CSIRO’s Australian Animal Health Laboratory and the Henry M Jackson Foundation, the facility was contracted to manufacture batches of a monoclonal antibody that may be a potential therapeutic for Hendra virus infection in humans.  

In a separate collaboration with Biosceptre, NBF is working to further develop a bioprocess for antibody production ahead of pre-clinical trials for the advancement of biologics targeting cancerous tumours.  

Contact information

Main contacts: AIBN (Qld) – jff Hou, CSIRO (Vic) – George Lovrecz
Email: AIBN –, CSIRO –
Phone: AIBN – +61 (0)7 3346 3178, CSIRO – +61 (0)3 9662 7348



Cell Line Development

  • Stable and transient protein expression systems
  • High throughput equipment

Upstream Production

  • Research to pilot scale (0.1-100L)
  • Stirred tank and disposable systems

Downstream Processing

  • State-of-the art recovery and purification systems
  • Capable of producing milligrams to grams of protein
  • Process development

Antibody Engineering

  • Functional antibody isolation and optimisation
  • Access to antibody phage library

Protein Analytics

  • Capacity for protein/peptide characterization including assessment of protein stability during storage, transport and use.

Product Quality Control

  •  ELISA
  • Glycan Fingerprinting
  • Endotoxin level testing